TipRanks (Tue, 21-Jul 7:50 AM ET)
TipRanks (Tue, 21-Jul 7:40 AM ET)
TipRanks (Tue, 21-Jul 7:20 AM ET)
TipRanks (Tue, 21-Jul 7:10 AM ET)
TipRanks (Tue, 21-Jul 7:00 AM ET)
4D Molecular releases phase 2 data for wet AMD asset 4D-150
Seeking Alpha News (Mon, 20-Jul 10:29 AM ET)
TipRanks (Mon, 20-Jul 9:20 AM ET)
4D Molecular Therapeutics Posts Strong 4D-150 Trial Results
TipRanks (Mon, 20-Jul 8:58 AM ET)
4D-150’s Durable Efficacy and Clean Safety Profile Support Buy Rating and Unchanged $36 Price Target
TipRanks (Mon, 20-Jul 6:15 AM ET)
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
Globe Newswire (Sat, 18-Jul 3:15 PM ET)
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
4D Molecular Therapeutics trades on the NASDAQ stock market under the symbol FDMT.
As of July 21, 2026, FDMT stock price climbed to $11.31 with 845,969 million shares trading.
FDMT has a beta of 0.35, meaning it tends to be less sensitive to market movements. FDMT has a correlation of 0.00 to the broad based SPY ETF.
FDMT has a market cap of $591.23 million. This is considered a Small Cap stock.
Last quarter 4D Molecular Therapeutics reported $3 million in Revenue and -$1.01 earnings per share. This beat revenue expectation by $223,000 and missed earnings estimates by -$.02.
In the last 3 years, FDMT traded as high as $36.25 and as low as $2.24.
The top ETF exchange traded funds that FDMT belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWN.
FDMT has outperformed the market in the last year with a return of +168.0%, while the SPY ETF gained +20.5%. In the last 3 month period, FDMT beat the market returning +12.3%, while SPY returned +5.9%. However, in the most recent 2 weeks FDMT has underperformed the stock market by returning -11.1%, while SPY returned -0.4%.
FDMT support price is $10.48 and resistance is $11.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that FDMT shares will trade within this expected range on the day.
